carnitine has been researched along with Shock, Septic in 24 studies
Shock, Septic: Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-carnitine is a potent antioxidant." | 6.82 | L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management. ( Avan, R; Habtemariam, S; Hashemi, J; Monajati, M; Negintaji, S; Saghafi, F; Sahebnasagh, A, 2022) |
| "Sepsis is defined as the dysregulated host response to an infection resulting in life-threatening organ dysfunction." | 6.58 | A review of micronutrients in sepsis: the role of thiamine, l-carnitine, vitamin C, selenium and vitamin D. ( Belsky, JB; Jacob, V; Lee, PJ; Sather, JE; Wira, CR, 2018) |
| "Carnitine deficiency was suspected, as the patient was malnourished and chronically taking valproic acid." | 5.56 | Refractory Hyperlactatemia After a Septic Shock in a Patient With Carnitine Deficiency: A Case Report. ( Brindamour, D; Demers-Marcil, S; Dupuis, S; Fortier, M; Hogan, P; Lagrenade-Verdant, C; Plourde, R, 2020) |
| "Carnitine treatment significantly lowered the tumour-induced rise in TG (% rise) in the sarcoma model (700 +/- 204 vs 251 +/- 51, P < 0." | 5.29 | Effects of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. ( Fiskum, G; Gallo, LL; Winter, BK, 1995) |
| "l-Carnitine is a candidate therapeutic for the treatment of septic shock, a condition that carries a ≥40% mortality." | 2.90 | Untargeted Metabolomics Differentiates l-Carnitine Treated Septic Shock 1-Year Survivors and Nonsurvivors. ( Evans, CR; Jones, AE; Karnovsky, A; Michailidis, G; Puskarich, MA; Stringer, KA, 2019) |
| "L-carnitine is a potent antioxidant." | 2.82 | L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management. ( Avan, R; Habtemariam, S; Hashemi, J; Monajati, M; Negintaji, S; Saghafi, F; Sahebnasagh, A, 2022) |
| "Sepsis and septic shock are severe and difficult-to-treat conditions with high lethality." | 2.82 | The supplementation of L-carnitine in septic shock patients: Systematic review and meta-analysis. ( Guedes, GV; Minicucci, MF; Tanni, SE, 2022) |
| "l-Carnitine-treated low-ketone patients had greater use of carnitine as evidenced by lower post-treatment l-carnitine levels." | 2.80 | Pharmacometabolomics of l-carnitine treatment response phenotypes in patients with septic shock. ( Finkel, MA; Harris, BN; Jones, AE; Karnovsky, A; Puskarich, MA; Stringer, KA; Trexel, J, 2015) |
| " The primary safety outcome was difference in serious adverse events (SAEs) per patient between groups." | 2.79 | Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: a randomized control trial. ( Claremont, H; Jones, AE; Kline, JA; Krabill, V; Puskarich, MA, 2014) |
| "Sepsis is defined as the dysregulated host response to an infection resulting in life-threatening organ dysfunction." | 2.58 | A review of micronutrients in sepsis: the role of thiamine, l-carnitine, vitamin C, selenium and vitamin D. ( Belsky, JB; Jacob, V; Lee, PJ; Sather, JE; Wira, CR, 2018) |
| "L-carnitine has shown promise for septic shock, but a recent phase II study of patients with vasopressor-dependent septic shock demonstrated a non-significant reduction in mortality." | 1.62 | Pharmacometabolomics identifies candidate predictor metabolites of an L-carnitine treatment mortality benefit in septic shock. ( Evans, CR; Flott, TL; Gillies, CE; Jennaro, TS; Jones, AE; Karnovsky, A; McHugh, CE; Puskarich, MA; Stringer, KA, 2021) |
| "Carnitine deficiency was suspected, as the patient was malnourished and chronically taking valproic acid." | 1.56 | Refractory Hyperlactatemia After a Septic Shock in a Patient With Carnitine Deficiency: A Case Report. ( Brindamour, D; Demers-Marcil, S; Dupuis, S; Fortier, M; Hogan, P; Lagrenade-Verdant, C; Plourde, R, 2020) |
| "L-Carnitine treatment increased levels of all measured acylcarnitines; an effect that was sustained for at least 36 h following completion of the infusion and was more prominent among nonsurvivors." | 1.48 | Septic Shock Nonsurvivors Have Persistently Elevated Acylcarnitines Following Carnitine Supplementation. ( Das, AK; Evans, CR; Jones, AE; Karnovsky, A; Puskarich, MA; Stringer, KA, 2018) |
| "Sepsis is the response of the host to an infection that produces lesions in its own organs and tissues." | 1.42 | Metabolite analysis in sepsis through conditional independence maps. ( Artigas, A; Brunelli, L; Ferrer, R; Goma, G; Navas, A; Pastorelli, R; Ribas Ripoll, V; Romay, E, 2015) |
| "The design incorporates a variety of features to increase efficiency, including a normal dynamic linear dose-response model, adaptive randomization, and early stopping for futility or success based on the probability that a future phase III trial using a 28-day mortality outcome would be successful." | 1.39 | An adaptive, phase II, dose-finding clinical trial design to evaluate L-carnitine in the treatment of septic shock based on efficacy and predictive probability of subsequent phase III success. ( Berry, SM; Broglio, K; Jones, AE; Lewis, RJ; Viele, K, 2013) |
| "Carnitine treatment significantly lowered the tumour-induced rise in TG (% rise) in the sarcoma model (700 +/- 204 vs 251 +/- 51, P < 0." | 1.29 | Effects of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. ( Fiskum, G; Gallo, LL; Winter, BK, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.50) | 18.7374 |
| 1990's | 6 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 5 (20.83) | 2.80 |
| Authors | Studies |
|---|---|
| Sahebnasagh, A | 1 |
| Avan, R | 1 |
| Monajati, M | 1 |
| Hashemi, J | 1 |
| Habtemariam, S | 1 |
| Negintaji, S | 1 |
| Saghafi, F | 1 |
| Guedes, GV | 1 |
| Minicucci, MF | 1 |
| Tanni, SE | 1 |
| Jennaro, TS | 2 |
| Puskarich, MA | 7 |
| McCann, MR | 1 |
| Gillies, CE | 2 |
| Pai, MP | 1 |
| Karnovsky, A | 5 |
| Evans, CR | 4 |
| Jones, AE | 8 |
| Stringer, KA | 5 |
| McHugh, CE | 1 |
| Flott, TL | 1 |
| Das, AK | 1 |
| Hogan, P | 1 |
| Plourde, R | 1 |
| Fortier, M | 1 |
| Brindamour, D | 1 |
| Lagrenade-Verdant, C | 1 |
| Demers-Marcil, S | 1 |
| Dupuis, S | 1 |
| Belsky, JB | 1 |
| Wira, CR | 1 |
| Jacob, V | 1 |
| Sather, JE | 1 |
| Lee, PJ | 1 |
| Ventz, S | 1 |
| Alexander, BM | 1 |
| Trippa, L | 1 |
| Shapiro, NI | 1 |
| Guirgis, FW | 1 |
| Runyon, M | 1 |
| Adams, JY | 1 |
| Sherwin, R | 1 |
| Arnold, R | 1 |
| Roberts, BW | 1 |
| Kurz, MC | 1 |
| Wang, HE | 1 |
| Kline, JA | 2 |
| Courtney, DM | 1 |
| Trzeciak, S | 1 |
| Sterling, SA | 1 |
| Nandi, U | 1 |
| Patki, D | 1 |
| Viele, K | 2 |
| Michailidis, G | 1 |
| Lewis, RJ | 1 |
| Broglio, K | 1 |
| Berry, SM | 1 |
| Krabill, V | 1 |
| Claremont, H | 1 |
| Finkel, MA | 1 |
| Trexel, J | 1 |
| Harris, BN | 1 |
| Ribas Ripoll, V | 1 |
| Romay, E | 1 |
| Brunelli, L | 2 |
| Pastorelli, R | 2 |
| Goma, G | 1 |
| Navas, A | 1 |
| Artigas, A | 1 |
| Ferrer, R | 1 |
| Ferrario, M | 1 |
| Cambiaghi, A | 1 |
| Giordano, S | 1 |
| Caironi, P | 1 |
| Guatteri, L | 1 |
| Raimondi, F | 1 |
| Gattinoni, L | 1 |
| Latini, R | 1 |
| Masson, S | 1 |
| Ristagno, G | 1 |
| Winter, BK | 1 |
| Fiskum, G | 1 |
| Gallo, LL | 1 |
| Famularo, G | 1 |
| De Simone, C | 1 |
| Keskin, S | 1 |
| Seven, A | 1 |
| Mert, M | 1 |
| Akalp, F | 1 |
| Yurdakul, F | 1 |
| Candan, G | 1 |
| Mela-Riker, L | 1 |
| Bartos, D | 1 |
| Vlessis, AA | 1 |
| Widener, L | 1 |
| Muller, P | 1 |
| Trunkey, DD | 1 |
| Lanza-Jacoby, S | 1 |
| Feagins, K | 1 |
| Bodine, R | 1 |
| Reibel, DK | 1 |
| Gullichsen, E | 1 |
| Takeyama, N | 1 |
| Takagi, D | 1 |
| Matsuo, N | 1 |
| Kitazawa, Y | 1 |
| Tanaka, T | 1 |
| Georgieff, M | 1 |
| DePalma, RG | 1 |
| Harano, Y | 1 |
| Robinson, AV | 1 |
| Holden, WD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of Levo-Carnitine for Vasopressor Dependent Septic Shock[NCT01665092] | Phase 2 | 250 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Use of Acetyl L-Carnitine in Patients With Covid-19 Pneumonia[NCT04623619] | 100 participants (Anticipated) | Interventional | 2020-12-15 | Not yet recruiting | |||
| Efficacy of Albumin Administration for Volume Replacement in Patients With Severe Sepsis or Septic Shock - the ALBumin Italian Outcome Sepsis (ALBIOS) Study[NCT00707122] | Phase 3 | 1,818 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Sequential Organ Failure Assessment Score (0-24 range). Delta SOFA is calculated as (SOFA Score at 48 hours post enrollment minus SOFA Score at enrollment). A negative value indicates improvement in the score. (NCT01665092)
Timeframe: 48 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Control | -1.8 |
| Carnitine Low | -0.34 |
| Carnitine Medium | -1.68 |
| Carnitine High | -2.15 |
4 reviews available for carnitine and Shock, Septic
| Article | Year |
|---|---|
L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management.
Topics: Carnitine; Fatty Acids; Humans; Sepsis; Shock, Septic | 2022 |
The supplementation of L-carnitine in septic shock patients: Systematic review and meta-analysis.
Topics: Adolescent; Adult; Carnitine; Dietary Supplements; Humans; Sepsis; Shock, Septic | 2022 |
A review of micronutrients in sepsis: the role of thiamine, l-carnitine, vitamin C, selenium and vitamin D.
Topics: Ascorbic Acid; Carnitine; Deficiency Diseases; Dietary Supplements; Humans; Micronutrients; Nutritio | 2018 |
Renal perfusion and metabolism in experimental endotoxin shock.
Topics: Animals; Atrial Natriuretic Factor; Blood Glucose; Carnitine; Catecholamines; Dogs; Energy Metabolis | 1991 |
5 trials available for carnitine and Shock, Septic
| Article | Year |
|---|---|
Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for Septic Shock: The Rapid Administration of Carnitine in Sepsis (RACE) Randomized Clinical Trial.
Topics: Aged; Carnitine; Female; Humans; Male; Middle Aged; Organ Dysfunction Scores; Placebos; Shock, Septi | 2018 |
Untargeted Metabolomics Differentiates l-Carnitine Treated Septic Shock 1-Year Survivors and Nonsurvivors.
Topics: 2-Aminoadipic Acid; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Carnitine; Chr | 2019 |
Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: a randomized control trial.
Topics: Aged; Black or African American; Body Mass Index; Cardiomyopathies; Carnitine; Dose-Response Relatio | 2014 |
Pharmacometabolomics of l-carnitine treatment response phenotypes in patients with septic shock.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Carnitine; Female; Humans; Magnetic Resonance Spectrosco | 2015 |
Mortality prediction in patients with severe septic shock: a pilot study using a target metabolomics approach.
Topics: Aged; Aged, 80 and over; Amino Acids; Carnitine; Cohort Studies; Female; Glycerophospholipids; Gram- | 2016 |
15 other studies available for carnitine and Shock, Septic
| Article | Year |
|---|---|
Using l-Carnitine as a Pharmacologic Probe of the Interpatient and Metabolic Variability of Sepsis.
Topics: Administration, Intravenous; Carnitine; Dose-Response Relationship, Drug; Humans; Precision Medicine | 2020 |
Pharmacometabolomics identifies candidate predictor metabolites of an L-carnitine treatment mortality benefit in septic shock.
Topics: Aged; Carnitine; Clinical Trials, Phase II as Topic; Death; Female; Humans; Male; Metabolomics; Midd | 2021 |
Septic Shock Nonsurvivors Have Persistently Elevated Acylcarnitines Following Carnitine Supplementation.
Topics: Aged; Carnitine; Fatty Acids; Female; Humans; Insulin; Magnetic Resonance Spectroscopy; Male; Middle | 2018 |
Refractory Hyperlactatemia After a Septic Shock in a Patient With Carnitine Deficiency: A Case Report.
Topics: Carnitine; Female; Humans; Hyperlactatemia; Intensive Care Units; Malnutrition; Middle Aged; Shock, | 2020 |
Bayesian Adaptive Randomization in Dose-Finding Trials.
Topics: Bayes Theorem; Carnitine; Humans; Random Allocation; Sepsis; Shock, Septic | 2018 |
An adaptive, phase II, dose-finding clinical trial design to evaluate L-carnitine in the treatment of septic shock based on efficacy and predictive probability of subsequent phase III success.
Topics: Administration, Intravenous; Carnitine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase I | 2013 |
Metabolite analysis in sepsis through conditional independence maps.
Topics: Adult; Aged; Algorithms; Bayes Theorem; Biomarkers; Carnitine; Computer Graphics; Critical Care; Fem | 2015 |
Effects of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock.
Topics: Animals; Cachexia; Carnitine; Cytokines; Infusion Pumps, Implantable; Interleukin-1; Interleukin-6; | 1995 |
A new era for carnitine?
Topics: Acquired Immunodeficiency Syndrome; Carnitine; Fatigue Syndrome, Chronic; Humans; Shock, Septic | 1995 |
Could L-carnitine be an acute energy inducer in catabolic conditions?
Topics: Carnitine; Child; Child, Preschool; Energy Metabolism; Epilepsy; Female; Humans; Infant; Male; Shock | 1997 |
Chronic hyperdynamic sepsis in the rat. II. Characterization of liver and muscle energy metabolism.
Topics: Adenine Nucleotides; Animals; Bacteroides fragilis; Blood Glucose; Carnitine; Cytochromes; Energy Me | 1992 |
Impaired carnitine transport in the rat heart during E. coli sepsis.
Topics: Animals; Biological Transport; Carnitine; Dose-Response Relationship, Drug; Escherichia coli Infecti | 1991 |
Altered hepatic fatty acid metabolism in endotoxicosis: effect of L-carnitine on survival.
Topics: Animals; Carnitine; Carnitine O-Acetyltransferase; Carnitine O-Palmitoyltransferase; Coenzyme A; Coe | 1989 |
[Metabolic effect of intravenously administered glucose, xylose or glycerin in various dosages and combinations].
Topics: Animals; Blood Glucose; Carnitine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ener | 1986 |
Structure and function of hepatic mitochondria in hemorrhage and endotoxemia.
Topics: Adenosine Diphosphate; Animals; Carnitine; Endotoxins; Escherichia coli; In Vitro Techniques; Ketogl | 1970 |